Edition:
India

Crinetics Pharmaceuticals Inc (CRNX.OQ)

CRNX.OQ on NASDAQ Stock Exchange Global Select Market

12.04USD
9:05pm IST
Change (% chg)

$-0.44 (-3.53%)
Prev Close
$12.48
Open
$12.20
Day's High
$12.58
Day's Low
$11.71
Volume
16,431
Avg. Vol
63,820
52-wk High
$26.65
52-wk Low
$10.63

Summary

Name Age Since Current Position

Wendall Wierenga

72 2015 Independent Chairman of the Board

R. Scott Struthers

58 2008 President, Chief Executive Officer, Director

Marc Wilson

41 2018 Chief Financial Officer

Adriana Cabre

2020 Vice President of Human Resources

Alan Krasner

56 2018 Chief Medical Officer

Ajay Madan

52 2020 Chief Development Officer

Camille Bedrosian

67 2020 Independent Director

Matthew Fust

55 2018 Independent Director

Stephen Kaldor

58 2015 Independent Director

Weston Nichols

35 2018 Independent Director

Stephanie Okey

60 2019 Independent Director

Biographies

Name Description

Wendall Wierenga

Dr. Wendall Wierenga Ph.D. serves as Independent Chairman of the Board of the Company. Dr. Wierenga brings to our board over four decades of experience in research, drug discovery and drug development, including clinical research, regulatory affairs, manufacturing, safety, and medical affairs. He has an extensive background serving as a public company executive and board member in the pharmaceutical and biotechnology industries. He most recently served as Executive Vice President, Research and Development, at Santarus, Inc., a specialty biopharmaceutical company, from June 2011 until its acquisition by Salix Pharmaceuticals, Inc. in 2014. Prior to Santarus, he was Executive Vice President of Research and Development at Ambit Biosciences Corporation from 2007 until 2011 and Neurocrine Biosciences, Inc. from 2003 until 2006. Additionally, Dr. Wierenga served as Chief Executive Officer of Syrrx, Inc. (now part of Takeda Pharmaceutical Company), Senior Vice President of Worldwide Pharmaceutical Sciences, Technologies and Development at Parke-Davis/Warner Lambert Company LLC (now Pfizer, Inc.), and he spent 16 years at Upjohn Pharmaceuticals in research and drug discovery roles. Dr. Wierenga serves as a member of the board of directors of Dermata Therapeutics, LLC, a private company. He also serves on the board of Cytokinetics Inc., a publicly-traded biopharmaceutical company. He was previously on the board of directors of Onyx Pharmaceuticals, Inc. (acquired by Amgen), Anacor Pharmaceuticals Inc. (acquired by Pfizer) XenoPort, Inc. (acquired by Arbor Pharmaceuticals), Ocera Therapeutics Inc. (acquired by Mallinckrodt), Apricus Biosciences, Inc. (acquired by Seelos), Patara Pharma LLC (acquired by Respivant), and Concert Pharmaceuticals, Inc. Additionally, Dr. Wierenga serves on several scientific advisory boards, including Sojournix, Inc., Ferring Pharmaceuticals, and Ocelot Bio. He holds a Ph.D. in Chemistry from Stanford University and a B.A. in Chemistry from Hope College. Dr. Wierenga’s scientific.

R. Scott Struthers

Dr. R. Scott Struthers Ph.D. serves as President, Chief Executive Officer, Director of the Company. Prior to Crinetics, he was senior director and head of endocrinology and metabolism at Neurocrine Biosciences, Inc., from 1998 to 2008. At Neurocrine, he initiated and led the company’s efforts to discover and develop orally active, nonpeptide GnRH antagonists, including elagolix. Prior to Neurocrine, from 1995 to 1998, he co-founded ScienceMedia Inc. to develop eLearning solutions for the life sciences and higher education markets and led contract research efforts at Biosym Technologies, from 1992 to 1995, to develop and apply computational tools for drug discovery. Dr. Struthers is also a co-founder of the San Diego Entrepreneurs Exchange, a nonprofit organization which he has served on the board of directors of since January 2009. He holds a Ph.D. in physiology and pharmacology from the University of California, San Diego based on the work he performed at the Salk Institute for Biological Studies. Dr. Struthers’ knowledge of our business, as well as his extensive development and clinical experience, contributed to our board of directors’ conclusion that he should serve as a director of our company.

Marc Wilson

Mr. Marc Wilson CPA serves as Chief Financial Officer of the Company. Prior to Crinetics, Mr. Wilson was Vice President of Finance and Accounting and Chief Accounting Officer at Cidara Therapeutics, Inc., a publicly-traded biotechnology company, from September 2014 to January 2018. Prior to Cidara, from October 2010 to August 2014, Mr. Wilson was Director of Accounting and Controller at Trius Therapeutics, a biopharmaceutical company, until its acquisition by Cubist Pharmaceuticals. Prior to Trius, Mr. Wilson worked at Neurocrine Biosciences, Inc. from 2007 to 2010. Mr. Wilson began his career in 2001 with PricewaterhouseCoopers LLP and is a certified public accountant. Mr. Wilson earned a bachelor’s degree in Economics and Accounting from the College of the Holy Cross.

Adriana Cabre

Ms. Adriana Cabre serves as Vice President of Human Resources of the Company. Ms. Cabré brings over 25 years of experience in human resources to the role, most recently serving as President of ACC People Strategies, a consulting practice she founded to provide customized human resource solutions. Prior to that, Ms. Cabré served as Chief People Officer at National University from September 2016 through September 2019. From February 2014 to May 2016, she was Senior Vice President of Human Resources at MedImpact Healthcare Systems, Inc. From 2006 to 2014, Ms. Cabré served as Senior Director and then Vice President of Human Resources at Amylin Pharmaceuticals where she helped lead the effort to build their commercial organization. She has also served as a Human Resources Director for both CooperVision and Motorola. Ms. Cabré holds a B.A. in International Business from Duquesne University and an MBA from Nova Southeastern University.

Alan Krasner

Dr. Alan Seth Krasner M.D. serves as Chief Medical Officer of the Company. Dr. Krasner served as Global Clinical Development Lead at Shire plc, a global biotechnology company focused on the treatment of rare diseases. Before joining Shire, Dr. Krasner served from May 2008 to November 2015 as Chief Medical Officer for Biodel Inc., a specialty biopharmaceutical company focused on the treatment of diabetes. Prior to Biodel, from 2002 to 2008, Dr. Krasner served as Director in the Department of Clinical Research Metabolic Diseases at Pfizer Global Research and Development, where he was responsible for the design, execution, clinical analysis, and reporting of multiple, global clinical trials supporting registration of late stage drug candidates. Dr. Krasner served as a consulting physician at the Joslin Diabetes and Endocrinology Center of the Lawrence and Memorial Hospital in New London, Connecticut until July 2017. Dr. Krasner holds a B.S. from the Medical Education Honors Program at Northwestern University and a M.D. from Northwestern University Medical School. He completed his residency at Johns Hopkins Hospital in internal medicine and subsequently completed his fellowship at Johns Hopkins Hospital in endocrinology and metabolism.

Ajay Madan

Dr. Ajay Madan Ph.D. serves as Chief Development Officer of the Company. Previously, from May 2002 to July 2016, Dr. Madan worked at Neurocrine Biosciences, Inc., including as Vice President of Preclinical Development from February 2013 to July 2016, where he was responsible for drug metabolism, pharmacokinetics, toxicology, and clinical pharmacology in support of a number of drug discovery and development programs. Since 2004, Dr. Madan has also taught, and continues to teach, courses at the University of California San Diego (UCSD) on selecting promising drug candidates and preclinical drug discovery and development. Prior to Neurocrine, from 1994 to 2002, Dr. Madan worked at XenoTech LLC, an in vitro drug research company, including as the Chief Scientific Officer, from 2001 to 2002. Dr. Madan is an author of more than 50 scientific publications, and he has been a diplomat of the American Board of Toxicology since 2005. He holds a B.Pharm. degree from Birla Institute of Technology and a Ph.D. in pharmacology and toxicology from the University of Kansas.

Camille Bedrosian

Dr. Camille L. Bedrosian M.D. serves as Independent Director of the Company. Dr. Bedrosian currently serves as Executive Vice President and Chief Medical Officer of Ultragenyx Pharmaceutical Inc. where she oversees global development functions including medical affairs, clinical development, clinical operations, regulatory affairs, patient advocacy and engagement, biometrics, and drug safety/pharmacovigilance. In this position, she is responsible for providing strategic leadership across clinical development and translational research programs. Prior to Ultragenyx, Dr. Bedrosian held executive-level positions in global development at Alexion Pharmaceuticals, Inc. and ARIAD Pharmaceuticals, Inc. Earlier in her career, Dr. Bedrosian served in the clinical research and development department of Genetics Institute, Inc. (acquired by Wyeth Inc., now part of Pfizer Inc.), where she assumed roles of increasing responsibility, eventually overseeing the company’s hemophilia therapeutic area. Dr. Bedrosian earned her medical degree from Harvard Medical School, a Master of Science degree from MIT, and completed a residency and fellowship at Duke University School of Medicine. She currently serves as a Member of the MIT Corporation Visiting Committee for the department of biology.

Matthew Fust

Mr. Matthew K. Fust serves as Independent Director of the Company. Mr. Fust retired as Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, Inc., a biopharmaceutical company, where he served from January 2009 through its acquisition by Amgen Inc. in October 2013. From May 2003 to December 2008, Mr. Fust served as Chief Financial Officer at Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company. From 2002 to 2003, Mr. Fust served as Chief Financial Officer at Perlegen Sciences, a genetics company. Previously, he was Senior Vice President and Chief Financial Officer at ALZA Corporation, a pharmaceutical company, where he was an executive from 1996 until 2002. Mr. Fust serves on the board of directors of the following publicly traded companies: Atara Biotherapeutics, Inc., a biopharmaceutical company, MacroGenics, Inc., a biopharmaceutical company, and Ultragenyx Pharmaceutical, Inc., a biopharmaceutical company. Mr. Fust also serves on the board of directors of BlackThorn Therapeutics, Inc., a private biopharmaceutical company. Mr. Fust previously served on the board of directors of Sunesis Pharmaceuticals, Inc. from May 2005 until May 2017 and Dermira, Inc. from April 2014 until February 2020. Mr. Fust received a B.A. from the University of Minnesota and an M.B.A. from the Stanford University Graduate School of Business. Mr. Fust’s experience as a chief financial officer in the life sciences industry, his leadership and management experience, and his service as a director of other biopharmaceutical companies, contributed to our board of directors’ conclusion that he should serve as a director of our company. 9

Stephen Kaldor

Dr. Stephen W. Kaldor Ph.D. serves as Independent Director of the Company. Dr. Kaldor has over 25 years of experience in the biotech and pharmaceutical industries. He currently serves as Chairman of Kinnate Biopharma, Inc., a precision oncology company he previously co-founded and led as Chief Executive Officer. He also serves as Chief Executive Officer and a director of Fount Therapeutics, LLC, and as a strategic advisor for Fronthera US Pharmaceuticals LLC, both biotechnology companies. Dr. Kaldor previously served as President and Chief Executive Officer at Quanticel Pharmaceuticals, Inc., a privately-held cancer drug discovery company, from February 2011 until its acquisition by Celgene Corporation in October 2015. Prior to that, Dr. Kaldor served as President and Chief Executive Officer of Ambrx Inc., a biotechnology company from July 2007 to June 2010. He was the President and Chief Scientific Officer at Syrrx Inc., a privately-held biotechnology company, from March 2003 until its acquisition by Takeda San Diego, Inc., the U.S. Discovery Research Center for Takeda Pharmaceuticals, in March 2005, and he continued on as President and Chief Scientific Officer at Takeda until July 2007. Previously, he served on the board of directors of Resolute Therapeutics, Inc., a biotechnology company, from October 2016 through 2017, and as a scientific advisory board member of Crown Bioscience, Inc., a translational technology company, from January 2009 until its acquisition by Japan Synthetic Rubber Corporation in 2018. Previously, Dr. Kaldor served as a director of Furiex Pharmaceuticals, Inc., a publicly-traded biotechnology company, from November 2010 until its acquisition by Forest Laboratories, Inc. in 2014 and as a director of Amira Pharmaceuticals, Inc., a privately-held pharmaceutical company, from March 2008 until its acquisition by Bristol-Myers Squibb Company in 2011. He started his career at Eli Lilly and Company in 1990 and is a chemist by training.

Weston Nichols

Mr. Weston A. Nichols Ph.D. serves as Independent Director of the Company. Dr. Nichols has been the Founder and Managing Partner of Lynx1 Capital, a biotechnology focused investment fund. From April 2016 to March 2020, Dr. Nichols served as an analyst for Perceptive Advisors, a life sciences focused investment firm. From January 2015 to April 2016, Dr. Nichols was an analyst at Balyasny Asset Management, an investment management firm, and from May 2014 to December 2014, he was a biotechnology equity research associate at SunTrust Robinson Humphrey. Dr. Nichols holds a B.S. in biological engineering from Cornell University, and a Ph.D. in neuroscience from Caltech. Dr. Nichols’ experience as venture capitalist in the life science industry contributed to our board of directors’ conclusion that he should serve as a director of our company.

Stephanie Okey

Ms. Stephanie S. Okey serves as Independent Director of the Company. Ms. Okey served in various positions of increasing responsibility in the biopharmaceutical industry, first at Genentech, Inc., followed by 19 years at Genyzme, a Sanofi company. Ms. Okey’s management experience during her tenure at Genyzme included serving as Senior Vice President, Head of North America, Rare Diseases, and U.S. General Manager, Rare Diseases from August 2012 to July 2015 and as Vice President and General Manager, U.S. Genetic Diseases Business Unit from September 2011 to August 2012. Ms. Okey retired from Genzyme in July 2015. Since June 2018, Ms. Okey has served as a member of the board of directors of Albireo Pharma, Inc., a Nasdaq-listed biopharmaceutical company and since December 2018, Ms. Okey has served as a member of the board of directors of PTC Therapeutics, a Nasdaq-listed biopharmaceutical company. In addition, she previously served as a member of the board of directors of the California Life Sciences Association from October 2014 to January 2016. Ms. Okey received a B.S. degree in Zoology from The Ohio State University and a M.S. degree in Immunology and Medical Microbiology from Wright State University. Ms. Okey’s executive leadership experience in the life science industry and service on various biopharmaceutical company boards contributed to our board of directors’ conclusion that she should serve as a director of our company.

Basic Compensation

Name Fiscal Year Total

Wendall Wierenga

264,250

R. Scott Struthers

3,766,660

Marc Wilson

1,423,810

Adriana Cabre

--

Alan Krasner

1,545,780

Ajay Madan

--

Camille Bedrosian

--

Matthew Fust

241,750

Stephen Kaldor

231,750

Weston Nichols

229,250

Stephanie Okey

429,791
As Of  31 Dec 2019